Business Executive (Medical Representative)

Eris Lifesciences is seeking a Business Executive (Medical Representative) to manage field sales activities, engage with doctors and healthcare providers, and ensure effective product promotion. The involves achieving sales targets, building strong customer relationships, andentifying new growth opportunities.

Roles and Responsibilities:

• Plan and execute territory-wise sales strategies to achieve business targets
• Build and maintain strong relationships with doctors, hospitals, and healthcare professionals
• Promote company products through regular doctor visits and detailing activities
• Conduct product presentations and training sessions for customers
• entify new business opportunities through market research and networking
• Monitor competitor activities and provide market feedback to the management
• Analyze sales performance and implement strategies to improve outcomes
• Collaborate with internal teams to ensure smooth execution of sales initiatives
• Maintain accurate records of daily activities, calls, and reporting

Eris Lifesciences Ltd is a publicly listed Indian pharmaceutical company and a prominent player in the domestic branded formulations market. Ranked among the top companies in the Indian Pharmaceutical Market (IPM), Eris has built a strong presence in the cardio-metabolic segment within a relatively short span since its inception.

Founded with a vision to make a meaningful impact in the management of chronic diseases, the company has evolved into a well-established organization focused on specialist and super-specialist segments. Over the years, Eris has strengthened its leadership across key therapies while maintaining high prescription credibility among healthcare professionals. The company continues to emphasize scientific engagement and patient-centric initiatives to enhance clinical outcomes.

Growth & Strategic Expansion

In recent years, the company has taken significant steps to expand its portfolio and strengthen its market position:

• Entry into the injectables segment, a high-growth market in India
• Acquisition of Swiss Parenterals, adding:
  • 190+ molecules
  • Pipeline of 40+ new products
• Acquisition of Biocon’s India Branded Formulation business, enhancing:
  • Insulin portfolio with key brands like Basalog and Insugen
  • Presence in the critical care segment
• Strategic entry into the oncology segment, including monoclonal antibody portfolio